Dr. Li is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1500 Duarte Rd
Duarte, CA 91010Phone+1 626-256-4673Fax+1 626-301-8233
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2012 - 2015
New York Presbyterian Hospital (Cornell Campus)Residency, Internal Medicine, 2009 - 2012
Weill Cornell MedicineClass of 2009
Certifications & Licensure
CA State Medical License 2015 - 2027
NY State Medical License 2012 - 2017- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Study of Efficacy and Safety of PDR001 in Patients With Advanced or Metastatic, Well-differentiated, Non-functional Neuroendocrine Tumors of Pancreatic, Gastrointestinal (GI), or Thoracic Origin or Poorly-differentiated Gastroenteropancreatic Neuroendocrine Carcinoma (GEP-NEC) Start of enrollment: 2017 Feb 14
- IRX-2, Cyclophosphamide, and Nivolumab in Treating Patients With Recurrent or Metastatic and Refractory Liver Cancer Start of enrollment: 2019 Feb 21
Publications & Presentations
PubMed
- Geriatric Assessment-driven INterventions among Hospitalized older adults with cancer (GAIN-HOSP), a prospective pilot study.Leana Cabrera Chien, Can-Lan Sun, Heeyoung Kim, Carolina Uranga, Enrique Soto-Perez-de-Celis
Journal of Geriatric Oncology. 2025-01-01 - Efficacy and Safety of Atezolizumab plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma with Main Trunk and/or Contralateral Portal Vein Invasion in IMbrave150.Richard S Finn, Peter R Galle, Michel Ducreux, Ann-Lii Cheng, Norelle Reilly
Liver Cancer. 2024-12-01 - 3 citationsThe relationship of mental health symptoms to chemotherapy toxicity risk in older adults with cancer: Results from the geriatric assessment-driven intervention study.Reena V Jayani, Anahid Hamparsumian, Canlan Sun, Daneng Li, Leana Cabrera Chien
Cancer. 2024-11-15
Journal Articles
- A Phase 2 Multi-Institutional Study of Nivolumab for Patients with Advanced Refractory Biliary Tract CancerOlatunji B Alese, Daneng Li, Amit Mahipal, JAMA Oncology
Authored Content
- A Phase 2 Multi-Institutional Study of Nivolumab for Patients with Advanced Refractory Biliary Tract CancerMay 2020
- A Phase 2 Multi-Institutional Study of Nivolumab for Patients with Advanced Refractory Biliary Tract CancerMay 2020
Press Mentions
Independence Valued over Survival for Neuroendocrine Tumor PatientsDecember 30th, 2022- Longer Survival Not Top Priority for Some Patients with CancerDecember 28th, 2022
- First Patient Dosed with Experimental Cancer-Killing Virus in New TrialJune 10th, 2022
- Join now to see all
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
